Specify a stock or a cryptocurrency in the search bar to get a summary
Terns Pharmaceuticals Inc
TERNTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Address: 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404
Analytics
WallStreet Target Price
18.64 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures TERN
Dividend Analytics TERN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TERN
Stock Valuation TERN
Financials TERN
Results | 2019 | Dynamics |